Tobias Puengel

Charité - Universitätsmedizin Berlin

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (14)

Julie Sellau

Bernhard-Nocht-Institut für Tropenmedizin

GERMANY

View details

Scott Friedman

Dean for Therapeutic Discovery

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Jonathan Frederik Brozat

Charité - Universitätsmedizin Berlin

GERMANY

View details

Moritz Peiseler

Charité - Universitätsmedizin Berlin

GERMANY

View details

Albrecht Eisert

Assistent Professor

University Hospital

GERMANY

View details

Sander Lefere

Ghent University

BELGIUM

View details

Ludovic Vallier

Professor

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY

View details

Florian Kurth

Bernhard-Nocht-Institut für Tropenmedizin

GERMANY

View details

Bruno Lapauw

Ghent University Hospital

BELGIUM

View details

Raphael Mohr

Charité - Universitätsmedizin Berlin

GERMANY

View details

Lindsey Devisscher

Professor ZAP

BELGIUM

View details

Philipp Hohlstein

RWTH Aachen University

GERMANY

View details

Frank Tacke

GERMANY

View details

Alexander Wree

Charité - Universitätsmedizin Berlin

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tobias Puengel

Research Interests

Explore related searches

Contact this professor

Articles (16)

Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma.

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Acquisition of epithelial plasticity in human chronic liver disease

Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis

Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model.

Extracellular Vesicles May Predict Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial.

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients.

Monocyte dysregulation: consequences for hepatic infections

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Collaborators (14)

Julie Sellau

Scott Friedman

Jonathan Frederik Brozat

Moritz Peiseler

Albrecht Eisert

Sander Lefere

Ludovic Vallier

Florian Kurth

Bruno Lapauw

Raphael Mohr

Lindsey Devisscher

Philipp Hohlstein

Frank Tacke

Alexander Wree

Make your next move.